GFR is key marker of kidney function; IgAN is progressive autoimmune kidney disease that leads to kidney failure in many patients 1-3 Fabhalta is first and only approved complement inhibitor for ...
Novartis Fabhalta meets phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy: Basel Friday, October 17, 2025, 10:00 Hrs [IST] Novartis announ ...
ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX ...
Research shows that high intakes of dietary magnesium, an essential mineral for our health, may help lower blood pressure.
The Limb Salvage Clinic in San Antonio integrates cardiovascular and podiatric teams to help patients find solutions.
Community-acquired pneumonia is a major global health challenge that disproportionately affects vulnerable populations, ...
Johnson & Johnson MedTech CEO Tim Schmid said the company is entering its next phase of growth with a sharper focus on ...
In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1eGFR ...
inews.co.uk on MSN
11 changes every woman over 50 should make to age well
At this stage of life, it's vital to lift weights, avoid getting too thin, reduce alcohol and keep up to date with jabs ...
The complete blood count routine test provides a snapshot of your body's blood production and immunity. The test measures a variety of components in your blood, including red blood cells, white blood ...
Drug candidates spanning oncology, neurology, rare diseases and more are approaching critical development as the calendar turns to 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results